Youssef Sari1, Makiko Sakai, Jason M Weedman, George V Rebec, Richard L Bell. 1. Department of Pharmacology, College of Pharmacy and Pharmaceutical Sciences, University of Toledo, Health Science Campus, 3000 Arlington Avenue, Toledo, OH 43614, USA. youssef.sari@utoledo.edu
Abstract
AIMS: Changes in glutamatergic transmission affect many aspects of neuroplasticity associated with ethanol and drug addiction. For instance, ethanol- and drug-seeking behavior is promoted by increased glutamate transmission in key regions of the motive circuit. We hypothesized that because glutamate transporter 1 (GLT1) is responsible for the removal of most extracellular glutamate, up-regulation or activation of GLT1 would attenuate ethanol consumption. METHODS: Alcohol-preferring (P) rats were given 24 h/day concurrent access to 15 and 30% ethanol, water and food for 7 weeks. During Week 6, P rats received either 25, 50, 100 or 200 mg/kg ceftriaxone (CEF, i.p.), a β-lactam antibiotic known to elevate GLT1 expression, or a saline vehicle for five consecutive days. Water intake, ethanol consumption and body weight were measured daily for 15 days starting on Day 1 of injections. We also tested the effects of CEF (100 and 200 mg/kg, i.p.) on daily sucrose (10%) consumption as a control for motivated behavioral drinking. RESULTS: Statistical analyses revealed a significant reduction in daily ethanol, but not sucrose, consumption following CEF treatment. During the post treatment period, there was a recovery of ethanol intake across days. Dose-dependent increases in water intake were manifest concurrent with the CEF-induced decreases in ethanol intake. Nevertheless, CEF did not affect body weight. An examination of a subset of the CEF-treated ethanol-drinking rats, on the third day post CEF treatment, revealed increases in GTL1 expression levels within the prefrontal cortex and nucleus accumbens. CONCLUSIONS: These results indicate that CEF effectively reduces ethanol intake, possibly through activation of GLT1, and may be a potential therapeutic drug for alcohol addiction treatment.
AIMS: Changes in glutamatergic transmission affect many aspects of neuroplasticity associated with ethanol and drug addiction. For instance, ethanol- and drug-seeking behavior is promoted by increased glutamate transmission in key regions of the motive circuit. We hypothesized that because glutamate transporter 1 (GLT1) is responsible for the removal of most extracellular glutamate, up-regulation or activation of GLT1 would attenuate ethanol consumption. METHODS:Alcohol-preferring (P) rats were given 24 h/day concurrent access to 15 and 30% ethanol, water and food for 7 weeks. During Week 6, P rats received either 25, 50, 100 or 200 mg/kg ceftriaxone (CEF, i.p.), a β-lactam antibiotic known to elevate GLT1 expression, or a saline vehicle for five consecutive days. Water intake, ethanol consumption and body weight were measured daily for 15 days starting on Day 1 of injections. We also tested the effects of CEF (100 and 200 mg/kg, i.p.) on daily sucrose (10%) consumption as a control for motivated behavioral drinking. RESULTS: Statistical analyses revealed a significant reduction in daily ethanol, but not sucrose, consumption following CEF treatment. During the post treatment period, there was a recovery of ethanol intake across days. Dose-dependent increases in water intake were manifest concurrent with the CEF-induced decreases in ethanol intake. Nevertheless, CEF did not affect body weight. An examination of a subset of the CEF-treated ethanol-drinking rats, on the third day post CEF treatment, revealed increases in GTL1 expression levels within the prefrontal cortex and nucleus accumbens. CONCLUSIONS: These results indicate that CEF effectively reduces ethanol intake, possibly through activation of GLT1, and may be a potential therapeutic drug for alcohol addiction treatment.
Authors: Laura Saba; Sanjiv V Bhave; Nicholas Grahame; Paula Bice; Razvan Lapadat; John Belknap; Paula L Hoffman; Boris Tabakoff Journal: Mamm Genome Date: 2006-06-12 Impact factor: 2.957
Authors: Karen K Szumlinski; Mahdi E Diab; Raquel Friedman; Liezl M Henze; Kevin D Lominac; M Scott Bowers Journal: Psychopharmacology (Berl) Date: 2007-01-16 Impact factor: 4.530
Authors: B R Miller; J L Dorner; M Shou; Y Sari; S J Barton; D R Sengelaub; R T Kennedy; G V Rebec Journal: Neuroscience Date: 2008-02-15 Impact factor: 3.590
Authors: Zachary A Rodd; Mark W Kimpel; Howard J Edenberg; Richard L Bell; Wendy N Strother; Jeanette N McClintick; Lucinda G Carr; Tiebing Liang; William J McBride Journal: Pharmacol Biochem Behav Date: 2008-02-26 Impact factor: 3.533
Authors: Mark W Kimpel; Wendy N Strother; Jeanette N McClintick; Lucinda G Carr; Tiebing Liang; Howard J Edenberg; William J McBride Journal: Alcohol Date: 2007-03 Impact factor: 2.405
Authors: Hyung W Nam; Sally R McIver; David J Hinton; Mahesh M Thakkar; Youssef Sari; Fiona E Parkinson; Phillip G Haydon; Doo-Sup Choi Journal: Alcohol Clin Exp Res Date: 2012-02-06 Impact factor: 3.455
Authors: Hasan Alhaddad; Darren M Gordon; Richard L Bell; Erin E Jarvis; Zachary A Kipp; Terry D Hinds; Youssef Sari Journal: Neuroscience Date: 2020-04-27 Impact factor: 3.590
Authors: Moonnoh R Lee; Christina L Ruby; David J Hinton; Sun Choi; Chelsea A Adams; Na Young Kang; Doo-Sup Choi Journal: Neuropsychopharmacology Date: 2012-10-03 Impact factor: 7.853